skip to the content

27-10-2008
MabThera® continues to improve patient response in rheumatoid arthritis with multiple courses of treatment

  

 

11-6-2008
New evidence shows MabThera® is more effective than a second TNF inhibitor in rheumatoid arthritis patients who have interrupted anti-TNF therapy due to lack of efficacy

25-1-2008

MabThera® meets study primary endpoint in improving disease symptoms when used as first biologic therapy in patients with rheumatoid arthritis

13-6-2007
 Latest data show MabThera® provides significant and sustained relief from signs and symptoms of rheumatoid arthritis

1-2-2007
 Rituximab Consensus Statement Published Optimising B Cell Therapy in Rheumatoid Arthritis in the Clinic

11-11-2006
 Repeat treatment with MabThera® provides continuous improvement of quality of life in rheumatoid arthritis patients

11-7-2006
 MabThera® approved for use in rheumatoid arthritis in Europe

22-6-2006
New evidence shows MabThera® inhibits joint damage in patients with rheumatoid arthritis

2-6-2006
MabThera® recommended for approval in rheumatoid arthritis in Europe

1-3-2006
FDA approves first rheumatoid arthritis indication for Rituxan (MabThera®)

16-11-2005

MabThera® – a unique approach providing lasting benefits for patients with rheumatoid arthritis

6-9-2005
download pdf Roche files first rheumatoid arthritis indication for MabThera® in Europe

9-6-2005
download pdf Major study shows MabThera®, an innovative B cell therapy, to be highly effective in treating rheumatoid arthritis

6-4-2005
download pdf MabThera® significantly improves symptoms in patients with rheumatoid arthritis who inadequately responded to anti-TNFa therapies

2-11-2004
 Positive outcome confirms efficacy of MabThera® in moderate-severe rheumatoid arthritis